MONARCH: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (NASH/MASH)
Miricorilant Reduced Liver Fat and Cardiometabolic Disease Markers in a Phase 1b, Open-Label Dose-Finding Study in Patients with Non-Alcoholic Steatohepatitis (NASH)
Miricorilant reduced liver fat and cardiometabolic disease markers in a phase 1b, open-label dose-finding study in patients with non-alcoholic steatohepatitis (NASH)
ROSELLA (GOG-3073, ENGOT-OV72/MITO): A Phase 3 Study of Relacorilant + Nab‑paclitaxel vs. Nab‑paclitaxel in Platinum-Resistant Ovarian Cancer
Safety, Pharmacokinetics, and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator Dazucorilant in Healthy Volunteers
ROSELLA, GOG‑3073, ENGOT‑OV72/MITO: A Phase 3 Study of Relacorilant + Nab‑paclitaxel vs. Nab‑paclitaxel in Advanced, Platinum-resistant Ovarian Cancer
Safety, Pharmacokinetics, and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator Dazucorilant in Healthy Volunteers
Impact of Surgery or Medical Treatment With the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients With Cushing Syndrome
Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study
